Victor David W, Kodali Sudha, Noureddin Mazen, Brombosz Elizabeth W, Lopez Analisa, Basra Tamneet, Graviss Edward A, Nguyen Duc T, Saharia Ashish, Connor Ashton A, Abdelrahim Maen, Cheah Yee Lee, Simon Caroline J, Hobeika Mark J, Mobley Constance M, Ghobrial R Mark
Sherrie and Alan Conover Center for Liver Disease and Transplantation, Department of Medicine, Houston Methodist Hospital, Houston, TX 77030, United States.
Department of Medicine, Houston Methodist Hospital, Houston, TX 77030, United States.
World J Transplant. 2025 Sep 18;15(3):101997. doi: 10.5500/wjt.v15.i3.101997.
Metabolic dysfunction-associated steatohepatitis (MASH) is increasingly common, as is hepatocellular carcinoma (HCC) in the background of MASH. Liver transplantation (LT) provides superior long-term survival for patients with unresectable MASH-HCC, but not all patients have equal access to transplant. MASH-HCC disproportionately affects Hispanic patients, but minorities are less likely to undergo LT for HCC. Additionally, females also undergo LT at lower rates than males.
To investigate whether race/ethnicity and sex affect LT waitlist outcomes.
Records of adults with MASH-HCC in the United States Organ Procurement and Transplantation Network database listed for LT between 1/2015 and 12/2021 were analyzed.
Most of the 3810 patients waitlisted for LT for MASH-HCC were non-Hispanic (NH) white (71.2%) or Hispanic (23.4%), with only 49 (1.1%) NH Black candidates. Hispanics underwent LT at lower rates than NH whites (71.6% 78.4%, < 0.001), but race/ethnicity did not affect waitlist mortality ( = 0.06). Patients with Hispanic [hazard ratio (HR) = 0.85, 95%CI: 0.77-0.95, = 0.002] or Asian (HR = 0.79, 95%CI: 0.63-0.98, = 0.04) race/ethnicity were less likely to undergo LT. Women were also less likely to receive LT (male: HR = 1.16, 95%CI: 1.04-1.29, = 0.01). Patients in regions 1 and 9 were less likely to be transplanted as well ( = 0.07).
Hispanic patients are less likely to undergo LT for MASH-HCC, concerning given their susceptibility to MASH and HCC. There were very few NH Black candidates. Disparities were also unequal across regions, which is particularly concerning in states where at-risk populations have rising cancer incidence. Additional research is needed to identify strategies for mitigating these differences in access to LT for MASH-HCC.
代谢功能障碍相关脂肪性肝炎(MASH)日益常见,MASH背景下的肝细胞癌(HCC)亦是如此。肝移植(LT)为无法切除的MASH-HCC患者提供了更好的长期生存机会,但并非所有患者都能平等地获得移植机会。MASH-HCC对西班牙裔患者的影响尤为严重,但少数族裔接受HCC肝移植的可能性较小。此外,女性接受肝移植的比例也低于男性。
研究种族/民族和性别是否会影响肝移植等待名单的结果。
分析了2015年1月至2021年12月期间在美国器官获取与移植网络数据库中登记等待肝移植的MASH-HCC成年患者的记录。
在3810名等待肝移植的MASH-HCC患者中,大多数是非西班牙裔(NH)白人(71.2%)或西班牙裔(23.4%),只有49名(1.1%)NH黑人候选人。西班牙裔接受肝移植的比例低于NH白人(71.6%对78.4%,P<0.001),但种族/民族并不影响等待名单上的死亡率(P=0.06)。西班牙裔[风险比(HR)=0.85,95%置信区间:0.77-0.95,P=0.002]或亚洲(HR=0.79,95%置信区间:0.63-0.98,P=0.04)种族/民族的患者接受肝移植的可能性较小。女性接受肝移植的可能性也较小(男性:HR=1.16,95%置信区间:1.04-1.29,P=0.01)。第1和第9地区的患者接受移植的可能性也较小(P=0.07)。
考虑到西班牙裔患者对MASH和HCC的易感性,他们接受MASH-HCC肝移植的可能性较小。NH黑人候选人非常少。各地区之间的差异也不平等,在高危人群癌症发病率上升的州,这一点尤其令人担忧。需要进一步研究以确定减少MASH-HCC肝移植机会差异的策略。